
Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera
Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera
- First patient treated at PRIMAvera clinical site in Rome, Italy
- Follows successful implantations at clinical sites in France, Germany, the UK and the Netherlands
- PRIMAvera on track to read-out around the end of 2023
Paris, France, September13, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the successful first implantation of a patient in Italy in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (dry AMD).
This follows the approval of the PRIMAvera study by the Italian Ministry of Health and the opening of the first clinical site in Italy at the Complesso Ospedaliero San Giovanni Addolorata. The PRIMAvera study aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. The study was initiated in Q4 2020 in France. Pixium Vision has since established additional clinical sites and implanted patients in Germany, the UK and the Netherlands.
"We are very pleased to have successfully implanted the first patient in Italy with the Prima System as part of the expanding PRIMAvera pivotal study," said Prof. Andrea Cusumano,co-investigator of the PRIMAvera study for Italy."We have been following the development of the Prima System since its inception and we have seen the significant promise it shows for those suffering from dry AMD, a disease for which we struggle to provide acceptable solution and hope to patients and their families.PRIMA's small size and wireless design means the implantation is a straightforward procedure which can be completed with minimal surgery.We will move ahead now with further implantations and we look forwardto adding our efforts to the clinical assessment of this innovative technology."
The PRIMAvera study design is based on the positive data generated in a French feasibility study, showing the ability of patients with dry AMD to improve visual acuity with the Prima System.
A total of 38 patients will be implanted in the PRIMAvera study, an open-label, baseline-controlled, non-randomized, multi-center, prospective, single-arm pivotal trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 months, and the primary safety endpoint is the number and severity of device and procedure-related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with an assessment of the primary endpoints at 12 months after implantation.
The implantation of patients has been performed at five sites in France, four in Germany as well as the Moorfields Eye Hospital in the UK, the Rotterdam Eye Hospital in the Netherlands and Complesso Ospedaliero San Giovanni Addolorata in Italy. Pixium Vision anticipates recruitment will be completed by the end of 2022 leading to a read-out of the PRIMAvera study around the end of 2023.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.
For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr
Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Contacts
Pixium Vision Offer Nonhoff Chief Financial Officer investors@pixium-vision.com +33 1 76 21 47 68 | Media Relations LifeSci Advisors Sophie Baumont sophie@lifesciadvisors.com +33 6 27 74 74 49 | Investor Relations LifeSci Advisors Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Rapala VMC Corporation: Strong Team to Implement New 2024-2026 Global Strategy8.12.2023 17:01:00 CET | Press release
Press Release To accelerate its transformation process, Rapala VMC Corporation has today announced its new Global Management Team. The new management team, together with several other key managers all over the world, will focus on implementing the new strategic plan for 2024-26. An important part of the implementation process are clear and measurable projects that focus on improving profitability and working capital management. Rapala believes the normalization of the over-demand situation created by the coronavirusis nearing completion and believes the normalization of the market will benefit Rapala. The company is closely monitoring market trends and expects that the recovery will open up opportunities for new growth plans. Rapala's success is based not only on strong globally renowned brands, but also on skilled, professional and committed personnel. The company continuously invests in the development of its personnel and the improvement of working conditions to ensure a high level
Rapala VMC Corporation: Changes in Global Management Team8.12.2023 17:00:00 CET | Press release
Rapala VMC Corporation, Changes board/management/auditors, December 8, 2023 at 06:00 p.m. EET Jean-Philippe Nicolle, who is already a member of the Global Management Team and currently the Chief Financial Officer, has been appointed as Chief Operating Officer responsible for Business Performance, Finance Controlling and Internal Auditing as of January 1, 2024. Miikka Tarna has been appointed as a member of Global Management Team and Chief Financial Officer as of January 1, 2024. Tarna has worked for the Rapala VMC Group since 2010 and is currently Deputy Chief Financial Officer. Tuomas Akkanen has been appointed as a member of Global Management Team and Executive Vice President, Head of Group Supply Chain and Winter Sports as of January 1, 2024. Akkanen has worked for the Rapala VMC Group since 2017 and is currently head of Group Supply Chain and Winter Sports. Päivi Ohvo has been appointed as a member of Global Management Team and Executive Vice President, Human Resources, as of Janua
Switch auction results: Housing Financing Fund bond series HFF150644 and HFF1504348.12.2023 16:50:00 CET | Press release
Today HF Fund concluded two switch auctions in which owners of HFF150644 were invited to exchange the bonds for indexed RIKS 33 0321 Treasury bonds and owners of HFF150434 were invited to exchange the bonds for indexed RIKS 30 0701 Treasury bonds. Bids in the nominal amount of 11,069,000,000 were submitted for RIKS 33 0321, and bids in the nominal amount of 11,069,000,000 were accepted at a predetermined price of 102.150. In exchange, HF Fund will buy back HFF150644 bonds in the nominal amount of 9,798,017,270 at a predetermined price of 100.00. Bids in the nominal amount of 16,651,000,000 were submitted for RIKS 30 0701, and bids in the nominal amount of 12,150,000,000 were accepted at a predetermined price of 102.400. In exchange, HF Fund will buy back HFF150434 bonds in the nominal amount of 16,287,685,500 at a predetermined price of 100.00. Due to strong demand HF-Fund is considering a similar future offerings that will be announced in due course. Further information can be obtaine
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS8.12.2023 16:20:00 CET | Press release
Bid procedure, 2023-12-15BondsSWEDISH GOVERNMENT: 1061. SE0011281922. 2029-11-12 SWEDISH GOVERNMENT: 1062, SE0013935319, 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2023-12-15Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)1061: 700 million SEK +/-700 million SEK 1062: 700 million SEK +/-700 million SEK 1053: 700 million SEK +/-700 million SEK Highest permitted bid volume (corresponding nominal amount)1061: 700 million SEK per bid 1062: 700 million SEK per bid 1053: 700 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2023-12-19Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2023-12-08 This is a translation of the special
Placeringsf. Nykredit Invest (Kapitalforening) – estimerede udlodninger for 20238.12.2023 15:37:01 CET | pressemeddelelse
På baggrund af de skattepligtige indtægter for 2023 har Placeringsf. Nykredit Invest (Kapitalforening) nu estimeret følgende ureviderede udlodninger for foreningens afdelinger for 2023: AfdelingISINValutaUdbytte pr. andelDanske FokusaktierDK0060231777DKK12,90Kredit Fokus KLDK0061066842DKK0,00 Det bemærkes, at der alene er tale om estimerede udlodninger, hvorfor der vil kunne ske ændringer. Der gøres endvidere opmærksom på at fx handelsaktivitet mv. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Endelige estimerede udlodninger vil blive offentliggjort på Nasdaq Copenhagen A/S den 24. januar 2024 og forventes udbetalt til investorerne den 2. februar 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted, tlf. 44 55 92 00. Med venlig hilsen Placeringsforeningen Nykredit Invest Tage Fabrin-Brasted, direktør Vedhæftet fil FB_Plac_NI_estimerede_udlodninger_8_12_2023